| 901 |
Bone Marrow |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
5 |
| 902 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
58 |
| 903 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
34 |
| 904 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Italy
|
61 |
| 905 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome/Myeloproliferative neoplasm
|
Hematology
|
2025
|
Standard Therapy
|
NETHERLANDS
|
62 |
| 906 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Austria
|
68 |
| 907 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
70 |
| 908 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
66 |
| 909 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
77 |
| 910 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Ukraine
|
12 |
| 911 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
58 |
| 912 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
67 |
| 913 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
4 |
| 914 |
Apheresis |
Allogeneic
|
Myelofibrosis Myeloid Metaplasia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
73 |
| 915 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
56 |
| 916 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Italy
|
50 |
| 917 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
39 |
| 918 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Lithuania
|
43 |
| 919 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
66 |
| 920 |
Apheresis |
Allogeneic
|
Multiple Myeloma
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
61 |
| 921 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Austria
|
55 |
| 922 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Italy
|
69 |
| 923 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Denmark
|
67 |
| 924 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
United Kingdom
|
75 |
| 925 |
Apheresis |
Allogeneic
|
T – cell Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
24 |
| 926 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Belgium
|
68 |
| 927 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Ukraine
|
42 |
| 928 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
50 |
| 929 |
Apheresis |
Allogeneic
|
Prolymphocytic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
62 |
| 930 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
United Kingdom
|
62 |
| 931 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
69 |
| 932 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
85 |
| 933 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
54 |
| 934 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
39 |
| 935 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
45 |
| 936 |
Apheresis |
Autologous
|
Acute myeloid leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
59 |
| 937 |
Apheresis |
Allogeneic
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
68 |
| 938 |
Apheresis |
Allogeneic
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
68 |
| 939 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
73 |
| 940 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
66 |
| 941 |
Apheresis |
Autologous
|
Acute myeloid leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
69 |
| 942 |
Apheresis |
Autologous
|
Hodgkin lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
38 |
| 943 |
Apheresis |
Allogeneic
|
Tcell acute leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Romania
|
31 |
| 944 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Italy
|
37 |
| 945 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Sweden
|
69 |
| 946 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
55 |
| 947 |
Apheresis |
Allogeneic
|
Fanconi’s Anemia
|
Hematology
|
2025
|
Standard Therapy
|
Russia
|
14 |
| 948 |
Apheresis |
Allogeneic
|
Peripheral T-cell Lymphoma not otherwise specified
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
54 |
| 949 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
France
|
63 |
| 950 |
Apheresis |
Allogeneic
|
Myeloid Sarcoma
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
48 |
| 951 |
Apheresis |
Allogeneic
|
Other Myelofibrosis/Myelosclerosis
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
72 |
| 952 |
Apheresis |
Allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
11 |
| 953 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
37 |
| 954 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2025
|
Standard Therapy
|
Australia
|
59 |
| 955 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
35 |
| 956 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
51 |
| 957 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
59 |
| 958 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
70 |
| 959 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
70 |
| 960 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
66 |
| 961 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
63 |
| 962 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
66 |
| 963 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Italy
|
61 |
| 964 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
71 |
| 965 |
Apheresis |
Allogeneic
|
Chronic Lymphocytic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Czechia
|
45 |
| 966 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Brazil
|
61 |
| 967 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Hungary
|
35 |
| 968 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
NETHERLANDS
|
48 |
| 969 |
Apheresis |
Allogeneic
|
Mantle Cell Lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Ireland
|
62 |
| 970 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
62 |
| 971 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia, Myelodysplasia-Related
|
Hematology
|
2025
|
Standard Therapy
|
Russia
|
53 |
| 972 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
56 |
| 973 |
Apheresis |
Allogeneic
|
Myelofibrosis Myeloid Metaplasia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
68 |
| 974 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
70 |
| 975 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
62 |
| 976 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
53 |
| 977 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
52 |
| 978 |
Apheresis |
Autologous
|
Diffuse large B-cell lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
63 |
| 979 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
72 |
| 980 |
Apheresis |
Autologous
|
Central nervous system lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
64 |
| 981 |
Apheresis |
Allogeneic
|
Acute myeloid leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
74 |
| 982 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
65 |
| 983 |
Apheresis |
Allogeneic
|
T-cell prolymphocytic leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
53 |
| 984 |
Apheresis |
Autologous
|
Central nervous system lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
70 |
| 985 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
61 |
| 986 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
54 |
| 987 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
41 |
| 988 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
32 |
| 989 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
72 |
| 990 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
52 |
| 991 |
Apheresis |
Allogeneic
|
Chronic Myeloid Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
50 |
| 992 |
Apheresis |
Allogeneic
|
T-cell Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
17 |
| 993 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
66 |
| 994 |
Apheresis |
Allogeneic
|
Multiple Myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
49 |
| 995 |
Apheresis |
Allogeneic
|
Chronic Granulomatous Disease
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
5 |
| 996 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
55 |
| 997 |
Apheresis |
Allogeneic
|
Diffuse Large B-cell Lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
68 |
| 998 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
64 |
| 999 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
51 |
| 1000 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
58 |